Print

Purpose

The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).

Condition

Eligibility

Eligible Ages
Between 18 Years and 80 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m^2) - Scheduled to undergo an elective primary unilateral TKA surgery

Exclusion Criteria

  • History of previous TKA surgery on incident side Other protocol defined Inclusion/Exclusion criteria will apply.

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Suzetrigine (SUZ) 		Participants will receive SUZ for 14 days.
  • Drug: Suzetrigine
    Tablets for oral administration.
    Other names:
    • VX-548
    • JOURNAVX
Placebo Comparator
Placebo 		Participants will receive placebo matched to SUZ for 14 days
  • Drug: Placebo
    Placebo matched to SUZ for oral administration

Recruiting Locations

Memorial Hermann Village Office
Houston, Texas 77043

More Details

Status
Recruiting
Sponsor
Vertex Pharmaceuticals Incorporated

Study Contact

Medical Information
617-341-6777
medicalinfo@vrtx.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.